Reappraisal of recent clinical trials of angiogenic therapy in myocardial ischemia.
We review the clinical trials of angiogenic therapy for myocardial ischemia, focusing on why the results are unsatisfactory in more recent larger and better designed trials. Critical reappraisal of such trials, in view of the pathophysiologic complexity of the angiogenic process at a molecular level, suggests that the strategy of therapies based on a single growth factor protein or gene may not be adequate for optimal therapeutic response.
Teng
Carolyn J
CJ
McGill University Health Centre, Royal Victoria Hospital, 687 Pine Ave West, Suite S8.30, Montreal H3A 1A1, Canada.
Lachapelle
Kevin
K
Chiu
Ray C J
RC
D043925:Angiogenesis Inducing Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D005346:Fibroblast Growth Factors / Q000627:therapeutic use*; D006801:Humans; D017202:Myocardial Ischemia / Q000188:drug therapy*; D017211:Treatment Failure; D042461:Vascular Endothelial Growth Factor A / Q000627:therapeutic use*
D043925:Angiogenesis Inducing Agents; D042461:Vascular Endothelial Growth Factor A; D005346:Fibroblast Growth Factors